Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study - Summary - MDSpire
Advertisement
Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study
To evaluate the safety and effectiveness of adalimumab over 52 weeks in Japanese patients with pyoderma gangrenosum (PG), including those with prior TNF-α inhibitor exposure and concomitant steroid use.
Key Findings:
Adalimumab was well tolerated with no new safety concerns identified.
Adverse drug reactions (ADRs) occurred in 14.9% of patients, with serious ADRs in 9.0%.
57.7% of patients achieved a Physician Global Assessment score of 0/1, indicating complete or near-complete healing.
Interpretation:
The findings support the use of adalimumab in broader clinical settings, particularly for patients with large lesions and those on systemic steroids, suggesting its potential for diverse patient profiles.
Limitations:
The study was limited to a single country and may not represent global populations.
Exclusion of patients previously treated with adalimumab for PG may limit generalizability and the understanding of its long-term effects.
Conclusion:
Adalimumab is a safe and effective treatment option for PG, warranting its use in diverse patient profiles.
Join UCI Health at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2 in Chicago, as we showcase how Orange County’s only academic health system is advancing the future of cancer care.
Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...
